AI in Clinical Trials I
Once you find a promising drug or device, you need to take it through trials. This is another long and complicated process. We need to make sure that these products are safe and effective before they’re prescribed to large numbers of people. So many things about this process are difficult: deciding which patient population would […]
AI in Drug Discovery V
The companies focused on using AI in drug discovery fall into two categories: Information engines and disease models inform general drug discovery and can be used by the wider scientific community at the earliest stages of development Drug design and optimization vendors produce algorithms design to improve the drug design process and develop candidates […]
AI in Drug Discovery IV
Companies like Atomwise, Exscientia, InSilico Medicine, Insitro, HealX and Cyclica have been pursuing partnerships with big pharma along with the development of their own compounds. There are two main business models that we’re starting to see here. First, there’s the biotech startups that are using internal research and development to discover new drugs. Second, there’s […]
AI in Drug Discovery III
Biological processes are complex, and that means that they lead to multi-dimensional data that human beings struggle to wrap their heads around. The good news is that AI is the perfect tool to spot patterns in this kind of data, and startups are increasingly using it to improve drug discovery from start to finish, from […]
AI in Drug Discovery II
Built on language models, artificial intelligence-powered generators such as ChatGPT can be made to read the codes that make up the building blocks of the human body. Research has found that it’s possible to develop a generalizable program—a “genomic language model”—that could be applied to a variety of different tasks, instead of requiring scientists to […]
AI in Drug Discovery I
THE CALIFORNIA BIOMEDICAL RESEARCH ASSOCIATION says that it currently takes an average of 12 years for a drug in the US to go from the research lab to the patient. Only one in every thousand drugs that begins pre-clinical testing ever makes it to human testing, and that has to happen five times before one […]
Is Direct to Consumer a good business model for health AI companies?
One of the major benefits of AI-enabled healthcare solutions is that they provide a higher degree of personalization. As such, they could be a wise choice in the emerging direct-to-consumer health market. Companies are selling products that are meant to address basic health and wellness issues by providing personalized nutrition, personalized exercise programs, home […]
How difficult is it to commercialize health AI solutions? III
While we’ve examined the issues that are keeping the majority of buyers from immediately adopting healthcare AI solutions, there are still pockets of potential buyers who could become the early adopters. These buyers can see an immediate ROI and don’t need to wait for additional evidence or reimbursement. One such group consists of independent […]
How difficult is it to commercialize health AI solutions? II
If you work for an innovative company with an FDA-approved healthcare AI solution, it can be a shock when you realize that no one is lining up to buy your well-designed and full-of-value product. But there are no shortcuts, and you have to stand in line with everyone else unless you’ve generated evidence that your […]
How difficult is it to commercialize health AI solutions? I
In my discussions with leaders at cutting edge companies with FDA-approved products in healthcare AI, I’ve noticed a common thread. Most were surprised by how difficult it’s been to successfully sell FDA-approved solutions in radiology, pathology, ophthalmology, and more. They noted that medical centers aren’t sure how to use the solutions and are therefore cautious […]